List view / Grid view
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
10 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered a mutation in the ZBTB7A gene boosts the energy metabolism of acute myeloid leukaemia cells...
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
18 April 2016 | By Victoria White, Digital Content Producer
SEL24 is a dual inhibitor of PIM and FLT3 kinases. It is the first molecule with this mechanism of action to progress to such stage of development...
11 April 2016 | By Victoria White, Digital Content Producer
The collaboration aims to develop new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias...
30 March 2016 | By Victoria White
Scientists from Cincinnati Children's Hospital Medical Centre have already used it to identify promising drug targets for acute myeloid leukaemia (AML)...
29 March 2016 | By Victoria White
The findings, made by scientists at the National University of Singapore, open a new door to treating the AML more effectively...
10 March 2016 | By Victoria White
Scientists are a step closer to creating blood stem cells that could reduce the need for bone marrow transplants in patients with cancer or blood disorders...
2 March 2016 | By Victoria White
Researchers have discovered that a GSK-J4 can kill acute lymphoblastic leukaemia that involves the TAL-1 gene...
24 February 2016 | By Victoria White
Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that uses DNA origami packaging...
1 February 2016 | By Victoria White
Nordic Nanovector has been awarded the NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
20 October 2015 | By Victoria White
The surprise finding could lead to a powerful new therapy for leukaemia and possibly other cancers...
12 October 2015 | By Victoria White
Boehringer Ingelheim and Philogen have agreed on an exploratory trial investigating novel immunotherapy concepts for relapsed acute myeloid leukaemia patients...
29 July 2015 | By Victoria White
An international team of scientists have succeeded in decoding the molecular characteristics of an as yet incurable subtype of leukaemia...
